2024 Volume 13 Pages 38-45
Purpose: Few studies have investigated the treatment outcomes and adverse events after using jidabokuippo (JDI), including the concomitant use of Kampo prescriptions and analgesics. In this study, we retrospectively analyzed the efficacy and safety of JDI in real-world clinical practice.
Methods: The study included 306 patients who were treated with JDI. Treatment outcomes and adverse events were compared according to age, sex, presence or absence of comorbidities, concomitant use of Kampo prescriptions and analgesics, daily dose of JDI, duration of administration, and the starting time of administration. The patients were divided into two groups: effective and ineffective.
Results: Concomitant use of Kampo prescriptions and analgesics was observed in 14.1% and 58.2% of the patients, respectively. The efficacy rate of JDI was 97.7%. The duration of JDI treatment in the analgesic group was significantly longer than that in the non-analgesic group (p = 0.0100). None of the patients reported any adverse events.
Conclusion: The efficacy rate of JDI was as high as 97.7% and no adverse events were observed. Adverse events can be prevented by being cautious of the side effects of Kampo prescriptions. However, the rate of concomitant use of analgesics was high, and the effects of reducing the dosage and frequency of analgesics remains to be determined.
